Access. Assistance. Along the journey.

Exelixis Access Services® (EASE) provides a variety of support to help your patients get started on treatment as soon as possible. EASE can meet the unique needs of your patients and practice at each step along the access journey.

 

 

YOUR EASE CASE MANAGER

 

image
  • Your single point of contact at EASE
  • Can provide the status of your patients’ access journey
  • Offers prompt support with payer coverage, financial assistance, and treatment coordination
  • Provides proactive follow-up
EASE Enrollment

EASE Enrollment Form, including the EASE Co-pay Program and the Patient Assistance Program (PAP)

Download the form
EASE consent

EASE Patient Authorization Form to obtain consent for enrollment in EASE programs

Download the form
EASE co-pay

EASE Co-Pay Program

Enroll eligible patients
EASE Dose Exchange

EASE Dose Exchange Form to support patients who require a dose reduction

Download the form

HELP PATIENTS START AND STAY ON CABOMETYX® (cabozantinib)

image
CABOMETYX Quick Start Program

Helps your newly prescribed eligible patients quickly receive their therapy if they experience a payer decision delay of 5 days or more.*†

 

image
EASE Dose Exchange Program

Supports patients who require a dose reduction with a one-time free supply to help them transition to a lower dose.†

DETERMINE ELIGIBILITY FOR PATIENT FINANCIAL ASSISTANCE

image
EASE Co-pay Program

Lowers co-pays to no more than $10 per month for eligible commercially insured patients.†

 

image
EASE Patient Assistance Program (PAP)

Helps your eligible patients who cannot afford their drug costs receive CABOMETYX free of charge.†

 

SUPPORT FOR COVERAGE DETERMINATION

At your request, EASE can provide support with benefits investigations (BIs), prior authorization (PA) assistance, and appeals support and follow-up.

*Limited to the following ICD-10-CM diagnoses: C64, C64.1, C64.2, and C64.9. Additional restrictions may apply.
Additional restrictions and eligibility rules apply.

This description of the Exelixis Access Services® program is for informational purposes only. Exelixis makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.

CONTACT EASE FOR MORE INFORMATION AND TO ENROLL

image
CALL: 1-844-900-EASE (1-844-900-3273)
Monday to Friday, 8:00 AM to 8:00 PM ET
image
FAX: 1-844-901-EASE
(1-844-901-3273)
image
 

INDICATION

CABOMETYX® (cabozantinib) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Severe and fatal hemorrhages have occurred with CABOMETYX. In RCC trials, the incidence of Grade ≥3 hemorrhagic events was 3% in CABOMETYX patients. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.

Gastrointestinal (GI) Perforations and Fistulas: In RCC trials, GI perforations were reported in 1% of CABOMETYX patients. Fatal perforations occurred in patients treated with CABOMETYX. In RCC studies, fistulas were reported in 1% of CABOMETYX patients. Monitor patients for symptoms of perforations and fistulas, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a GI perforation or a fistula that cannot be appropriately managed.

Thrombotic Events: Thrombotic events increased with CABOMETYX. In RCC trials, venous thromboembolism occurred in 9% (including 5% pulmonary embolism) and arterial thromboembolism occurred in 1% of CABOMETYX patients. Fatal thrombotic events occurred in the cabozantinib clinical program. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.

Hypertension and Hypertensive Crisis: Treatment-emergent hypertension, including hypertensive crisis, increased with CABOMETYX. In RCC trials, hypertension was reported in 44% (18% Grade ≥3) of CABOMETYX patients. Monitor blood pressure prior to initiation and regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX if there is evidence of hypertensive crisis or for severe hypertension that cannot be controlled with antihypertensive therapy or medical management.

Diarrhea: In RCC trials, diarrhea occurred in 74% of CABOMETYX patients. Grade 3 diarrhea occurred in 11% of CABOMETYX patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 diarrhea or Grade 3-4 diarrhea that cannot be managed with standard antidiarrheal treatments until improvement to Grade 1; resume CABOMETYX at a reduced dose.

Palmar-Plantar Erythrodysesthesia (PPE): In RCC trials, PPE occurred in 42% of CABOMETYX patients. Grade 3 PPE occurred in 8% of CABOMETYX patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 PPE or Grade 3 PPE until improvement to Grade 1; resume CABOMETYX at a reduced dose.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in the cabozantinib clinical program. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Embryo-fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during CABOMETYX treatment and for 4 months after the last dose.

ADVERSE REACTIONS

The most commonly reported (≥25%) adverse reactions were: diarrhea, fatigue, nausea, decreased appetite, hypertension, PPE, weight decreased, vomiting, dysgeusia, and stomatitis.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If concomitant use with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage.

Strong CYP3A4 Inducers: If concomitant use with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed while taking CABOMETYX and for 4 months after the final dose.

Hepatic Impairment: In patients with mild to moderate hepatic impairment, reduce the CABOMETYX dosage. CABOMETYX is not recommended for use in patients with severe hepatic impairment.

Please see accompanying full Prescribing Information.